Inger Johansson

Inger Johansson

Auto-generated profile, based on publicly available information

Inger Johansson

Department of Physiology and Pharmacology Biomedicum B5, Karolinska Institutet Stockholm Sweden

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
THTracey Hurrell
Tracey Hurrell
VKVlasia Kastrinou-Lampou
Vlasia Kastrinou-Lampou
Achilleas FardellasAchilleas Fardellas
Achilleas Fardellas
DHDelilah F. G. Hendriks
Delilah F. G. Hendriks
ÅNÅsa Nordling
Åsa Nordling
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
Non-alcoholic fatty liver disease affects approximately one billion adults worldwide. Non-alcoholic steatohepatitis (NASH) is a progressive disease and underlies the advancement to liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which there are no FDA-approved drug therapies. We developed a hetero-cellular spheroid system comprised of primary human hepatocytes (PHH) co-cultured with crude fractions of primary human liver non-parenchymal cells (NPC) from several matched or non-matched donors, to identify phenotypes with utility in investigating NASH pathogenesis and drug screening. Co-culture spheroids displayed stable expression of hepatocyte markers (albumin, CYP3A4) with the integration of stellate (vimentin, PDGFRβ), endothelial (vWF, PECAM1), and CD68-positive cells. Several co-culture spheroids developed a fibrotic phenotype either spontaneously, primarily observed in PNPLA3 mutant donors, or after challenge with free fatty acids (FFA), as determined by COL1A1 and αSMA expression. This phenotype, as well as TGFβ1 expression, was attenuated with an ALK5 inhibitor. Furthermore, CYP2E1, which has a strong pro-oxidant effect, was induced by NPCs and FFA. This system was used to evaluate the effects of anti-NASH drug candidates, which inhibited fibrillary deposition following 7 days of exposure. In conclusion, we suggest that this system is suitable for the evaluation of NASH pathogenesis and screening of anti-NASH drug candidates.

20 March 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
HLHasan Çağın Lenk
Hasan Çağın Lenk
KKKatharina Klöditz
Katharina Klöditz
IJInger Johansson
Inger Johansson
RSRobert Løvsletten Smith
Robert Løvsletten Smith
MJMarin M. Jukić
Marin M. Jukić
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
The genetic background for interindividual variability of the polymorphic CYP2D6 enzyme activity remains incompletely understood and the role of NFIB genetic polymorphism for this variability was evaluated in this translational study. We investigated the effect of NFIB expression in vitro using 3D liver spheroids, Huh7 cells, and the influence of the NFIB polymorphism on metabolism of risperidone in patients in vivo. We found that NFIB regulates several important pharmacogenes, including CYP2D6. NFIB inhibited CYP2D6 gene expression in Huh7 cells and NFIB expression in livers was predominantly nuclear and reduced at the mRNA and protein level in carriers of the NFIB rs28379954 T>C allele. Based on 604 risperidone treated patients genotyped for CYP2D6 and NFIB, we found that the rate of risperidone hydroxylation was elevated in NFIB rs28379954 T>C carriers among CYP2D6 normal metabolizers, resulting in a similar rate of drug metabolism to what is observed in CYP2D6 ultrarapid metabolizers, with no such effect observed in CYP2D6 poor metabolizers lacking functional enzyme. The results indicate that NFIB constitutes a novel nuclear factor in the regulation of cytochrome P450 genes, and that its polymorphism is a predictor for the rate of CYP2D6 dependent drug metabolism in vivo.

1 September 2012
Verified
Journal Article
Closed access
KSKristina Stenstedt
Kristina Stenstedt
MHMaria Hallstrom
Maria Hallstrom
IJInger Johansson
Inger Johansson
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
PRPeter Ragnhammar
Peter Ragnhammar
DEDavid Edler
David Edler

22 April 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
IJInger Johansson
Inger Johansson
EXEmmanouella M. Xanthopoulou
Emmanouella M. Xanthopoulou
YZYitian Zhou
Yitian Zhou
ASAnabel Sanchez‐Spitman
Anabel Sanchez‐Spitman
MLMaaike van der Lee
Maaike van der Lee
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6‐mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes and phenotypes of patients in two large clinical cohorts, focusing on the metabolism of the CYP2D6 substrates risperidone and desmethyltamoxifen. The analysis incorporated novel polymorphic haplotypes and substrate‐specific differences among the CYP2D6.1, CYP2D6.2, and CYP2D6.35 enzyme variants. The study revealed that CYP2D6.2 and CYP2D6.35 exhibit reduced metabolic capacity for these substrates, both in vivo and in an in vitro expression model. This was evidenced by decreased catalytic turnover (Kcat), decreased substrate affinity, and altered substrate docking. Furthermore, novel polymorphic haplotypes on the CYP2D6*1, CYP2D6*2, and CYP2D6*35 backgrounds were identified, each associated with a 30–40% increase in CYP2D6 activity. Incorporating these findings into prediction equations significantly improved the genetic prediction accuracy (R2) for CYP2D6‐mediated metabolism of desmethyltamoxifen from 59% to 71% and risperidone, also metabolized by CYP3A4, from 42% to 46%. These results highlight the importance of accounting for drug‐specific interactions with enzyme variants and integrating distinct polymorphic haplotypes into CYP pharmacogenomic models and guidelines for better translation into clinical practice.

26 July 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
Chris Steven PridgeonChris Steven Pridgeon
Chris Steven Pridgeon
IJInger Johansson
Inger Johansson
MIMagnus Ingelman-Sundberg
Magnus Ingelman-Sundberg
During pharmacotherapy, knowledge about the actual drug and metabolite concentrations in plasma is often critical. Individual dose adjustments can be performed based on pre‐emptive genotyping of certain absorption, distribution, metabolism, and excretion (ADME) genes but also using therapeutic drug monitoring (TDM). Analyses of liquid biopsies for tumor‐derived components are well‐established and have been found to be a good complement to biopsy examinations. Recently, liquid biopsy‐based quantification of cell‐free RNA (cfRNA) in plasma exosomes was proposed as a proxy measurement for the expression of different hepatic ADME genes and for the rate of drug metabolism, constituting an alternative to TDM. In this study, we validated these findings by examining the correlation between mRNA expression of eight different CYP genes in liver and the corresponding rate of enzyme‐specific drug metabolism in 96 donor‐matched liver samples. Analyses of CYP‐dependent drug metabolism in liver microsomes in comparison to the level of mRNA expression for the different CYP genes revealed a mean Pearson correlation coefficient of 0.28. The highest correlations (0.33–0.34) were obtained for CYP2D6 and CYP3A4 and the weakest correlations were observed for CYP1A2 and CYP2B6 (0.18–0.21). In all cases, the correlations obtained were too weak to demonstrate a predictive relationship, likely due to different regulatory and post‐translational events controlling the rate of enzyme activity. Our results reinforce the notion that, whilst liquid biopsy‐based approaches might have utility for prediction of hepatic CYP protein expression, they are not currently an important substitute for TDM.

6 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PNPaola Nolé
Paola Nolé
BDBritt Duijndam
Britt Duijndam
ASAdam Stenman
Adam Stenman
CJCarl Christofer Juhlin
Carl Christofer Juhlin
MKMikael Kozyra
Mikael Kozyra
IJInger Johansson
Inger Johansson
Human cytochome P450 2W1 (CYP2W1) enzyme is expressed in fetal colon and in colon tumors. The level of expression is higher in colon metastases than in the parent tumors and the enzyme is a possible drug target for treatment of colorectal cancer, as demonstrated in mouse xenograft studies. A previous study published in this journal reported that CYP2W1 is highly expressed in normal and transformed adrenal tissue. However, adrenal expression of CYP2W1 protein was not seen in previous studies in our research group. To clarify this inconsistency, we have used qRT-PCR and Western blotting with CYP2W1-specific antibodies to probe a panel of 27 adrenocortical carcinomas and 35 normal adrenal cortex samples. CYP2W1 mRNA expression is seen in all samples. However, significant CYP2W1 protein expression was found in only one tumor sample (a testosterone-producing adrenocortical carcinoma) and not in any normal tissue. Differences in the specificity of the CYP2W1 antibodies used in the two studies may explain the apparent discrepancy. We conclude that normal adrenal tissue lacks P450 2W1 enzyme expression; also, adrenocortical carcinomas generally do not express the enzyme. This information thus underline the colon cancer specificity of CYP2W1 enzyme expression and has implications for the development of anti-colon cancer therapies based on CYP2W1 as a drug target, since 2W1-dependent bioactivation of prodrugs for CYP2W1 will not take place in normal adrenal tissue or other non-transformed tissues.